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Abstract: Background. Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction
(HFrEF) was shown to be superior to enalapril in reducing the risk of death and hospitalization for
HF. Our aim was to evaluate the cardiopulmonary effects of sacubitril/valsartan in patients with
HFrEF. Methods. We conducted an observational study. Ninety-nine ambulatory patients with HFrEF
underwent serial cardiopulmonary exercise tests (CPET) after initiation of sacubitril/valsartan in
addition to recommended therapy. Results. At baseline, 37% of patients had New York Heart
Association (NYHA) class III. After a median follow-up of 6.2 months (range 3–14.9 months)
systolic blood pressure decreased from 117 ± 14 to 101 ± 12 mmHg (p < 0.0001), left ventricular
ejection fraction (LVEF) increased from 27 ± 6 to 29.7 ± 7% (p < 0.0001), peak oxygen consumption
(VO2) improved from 14.6 ± 3.3 (% of predicted = 53.8 ± 14.1) to 17.2 ± 4.7 mL/kg/min (% of
predicted = 64.7 ± 17.8) (p < 0.0001), minute ventilation/carbon dioxide production relationship
(VE/VCO2 Slope) decreased from 34.1 ± 6.3 to 31.7 ± 6.1 (p = 0.006), VO2 at anaerobic threshold
increased from 11.3 ± 2.6 to 12.6 ± 3.5 mL/kg/min (p = 0.007), oxygen pulse increased from
11.5 ± 3.0 to 13.4 ± 4.3 mL/kg/min (p < 0.0001), and ∆VO2/∆Work increased from 9.2 ± 1.5 to
10.1 ± 1.8 mL/min/watt (p = 0.0002). Conclusion. Sacubitril/valsartan improved exercise tolerance,
LVEF, peak VO2, and ventilatory efficiency at 6.2 months follow-up. Further studies are necessary to
better clarify underlying mechanisms of this functional improvement.
Keywords: heart failure; sacubitril/valsartan; cardiopulmonary test; exercise tolerance
1. Introduction
Combining renin-angiotensin-aldosterone system blockade with natriuretic peptide system
enhancement may deliver functional benefits to patients with heart failure (HF) with reduced
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ejection fraction (HFrEF). In the PARADIGM-HF study, angiotensin receptor/neprilysin inhibitor
sacubitril/valsartan was shown to be superior to enalapril in reducing the risk of death and
hospitalization for HF [1]. However, little is known about the effects of sacubitril/valsartan on
cardiopulmonary function. Recent studies showed an improvement in exercise tolerance at 6-min
walk test (6-MWT) after initiation of sacubitril/valsartan in patients with HFrEF [2–4]. In this clinical
setting, only one study demonstrated an increase in peak oxygen consumption (VO2) after initiation
of sacubitril/valsartan, but it was limited by a small sample size (16 patients) and a very short-term
follow-up (1 month) [5].
Cardiopulmonary exercise test (CPET) is a valuable tool in HFrEF, allowing accurate assessment
of patients’ functional capacity and providing prognostically relevant parameters (e.g., peak VO2 and
minute ventilation/carbon dioxide production relationship [VE/VCO2 slope]) [6–10].
In this study, we sought to evaluate the effects of sacubitril/valsartan on prognostically significant
CPET parameters in a larger population of HFrEF patients and with a longer follow-up.
2. Materials and Methods
2.1. Patient Selection and Study Design
This prospective, observational study was approved by the Institutional Research Review
Boards of the Cardiovascular Rehabilitation Unit of Buccheri La Ferla Fatebenefratelli Hospital
and of the Department for the Treatment and Study of Cardiothoracic Diseases and
Cardiothoracic Transplantation IRCCS-ISMETT, Palermo, Italy. All patients provided informed consent.
This study complies with the principles of the Declaration of Helsinki and national regulations.
Sacubitril/valsartan was administered to patients with HFrEF, on top of guidelines recommended
therapy [11]. Patients were included in the study in accordance with the Italian reimbursement criteria
for sacubitril/valsartan: 1. symptomatic HF defined as New York Heart Association (NYHA) class
II–IV, 2. left ventricular ejection fraction below 35%, as measured using echocardiography, 3. previous
treatment with an individual optimal dose of angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker for at least 6 months, 4. systolic arterial blood pressure ≥100 mmHg, 5. serum K+
level <5.4 mEq/L, 6. estimated glomerular filtration rate >30 mL/min/1.73 m2, 7. absence of severe
liver insufficiency (Child-Pugh C), and 8. no history of angioedema.
In accordance with European Society of Cardiology Prevention guidelines, patients were
encouraged to have a minimum of 2.5 h a week of moderate intensity aerobic activity, in multiple
bouts each lasting ≥10 min, 5 days a week [12]. Patients were not engaged in exercise-based
cardiac rehabilitation, and physical activity was prescribed according to patient’s age, past habits,
comorbidities, preferences, and goals.
Exclusion criteria were: 1. hospitalization for HF within 90 days before ambulatory evaluation,
2. myocardial revascularization within 180 days before ambulatory evaluation, 3. concomitant initiation
of cardiac resynchronization therapy and/or percutaneous mitral valve treatment during study
follow-up or in the previous 6 months, 4. congenital heart disease, and 5. inability to perform CPET.
Sacubitril/valsartan was administered according to established guidelines [11]. Up-titration
was performed every 4 weeks, if tolerated by the patient. Changes in the dosage of diuretics were
allowed during the study follow-up if deemed necessary. N-terminal pro-brain natriuretic peptides
(NT-proBNP) serum levels were detected at baseline and at 3, 6, and 12 months.
2.2. CPET Protocol
Baseline CPET was performed before starting administration of sacubitril/valsartan. Serial
CPETs were performed at 3, 6, and 12 months. All CPETs were performed on a cycle ergometer at
60 rpm. A ramp protocol was systematically performed: work load started at 10 watts for 2 min
(warm-up) and increased by 10 watts every 60 s. Breath by breath analysis of expiratory O2, CO2,
and expired volumes was performed using the Vmax® 2900 metabolic cart (SensorMedics, Yorba
J. Clin. Med. 2019, 8, 262 3 of 12
Linda, CA, USA). Heart rate, 12 lead ECG, and oximetry (with pulse oximeter) were monitored
continuously. Patients were encouraged to exercise until they felt unable to continue because of
dyspnea or fatigue. The respiratory exchange ratio (RER) is the ratio between the amount of CO2
produced in metabolism and O2 used, representing a measure of exercise effort with RER > 1.05–1.10
indicating maximal effort [10]. Anaerobic threshold (i.e., the point during exercise when a switch
from aerobic to anaerobic metabolism occurs) was measured using the V-slope analysis from the plot
of carbon dioxide production (VCO2) versus VO2 and confirmed using ventilatory equivalents and
end-tidal pressures of CO2 and O2. The rate at which VO2 increased per watt of work (∆VO2/∆Work)
was calculated for the progressively increasing exercise period, beginning 1 min after work rate started
to increase. ∆VO2/∆Work slope and VO2 at anaerobic threshold (AT-VO2) were used as a measure
of muscle efficiency. The relationship between minute ventilation and carbon dioxide production
(VE/VCO2 slope) was used as a measure of ventilatory efficiency and was calculated from 1 min after
the beginning of loaded exercise up to the end of the isocapnic buffering period. Reported values
of VO2, ventilation, and tidal volume at peak exercise are the averages over the 30 s in which the
examined event occurred. Percent predicted VO2 represents the achieved peak VO2 adjusted for age,
weight, and height and expressed as a percentage. We measured percent predicted VO2 using the
equations by Wasserman and Hansen [13].
2.3. Statistical Analyses
Statistical analysis was performed using SAS JMP 9 software package. Continuous variables
are described as mean±standard deviation, or as median and interquartile (IQ) range, in case of
non-normal distribution. Categorical variables are expressed as number (percentages). Baseline and
follow-up CPET parameters were compared using a Mann-Whitney U test for continuous variables
and Fisher exact test for categorical variables, respectively. Changes from baseline were tested using
a paired t-test or McNemar test, as appropriate. A p-value <0.05 was considered statistically significant.
Nominal logistic regression was conducted to assess correlations between exercise tolerance, VO2,
and VE/VCO2. A 6% increase of VO2 from baseline was used as a cut-off to individuate a significant
improvement in VO2, according to current literature on this topic [10].
3. Results
3.1. Patients Characteristics
At present, a total of 125 patients have been enrolled and have undergone at least basal CPET.
The final population for this study consisted of 99 patients for whom at least 1 follow up CPET was
available (Figure 1). Baseline characteristics are listed in Table 1. Mean age was 58.7 ± 9.3 years, 86%
were males, 51% had ischemic heart disease, 63% were on NYHA class II, 37% were on NYHA class
III, and 17% were on atrial fibrillation. Mean left ventricular ejection fraction (LVEF) was 27 ± 6%.
The starting dose of sacubitril/valsartan was 24/26 mg in 69% of patients.
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Figure 1. Flow chart of the study design. ARNI: angiotensin receptor-neprilysin inhibitor; CPET: 
cardiopulmonary exercise test; HFrEF: heart failure with reduced ejection fraction. 
Table 1. Patient characteristics at baseline (n = 99). 
Demographics 
Age, year, mean ± SD 58.7 ± 9.3 
Female sex, no. (%) 14 (14) 
SBP, mmHg, mean ± SD 117 ± 14 
DBP, mmHg, mean ± SD 72 ± 10 
Heart rate, beats/min, mean ± SD 67 ± 11 
Body mass index, kg/m2, mean ± SD 28.1 ± 4.2 
Medical History 
Hypertension, no. (%) 51 (51)  
Diabetes, no. (%) 34 (34) 
Atrial fibrillation, no. (%) 17 (17) 
COPD, no. (%) 10 (10) 
eGFR, mL/min/1.73m2, mean ± SD 67.8 ± 23.7 
Nt-pro-BNP, median (IQ range) 1200 (446–2120) 
LVEF (%), mean ± SD 27 ± 6 
LVEDV, mL, mean ± SD 218 ± 57 
LVESV, mL, mean ± SD 153 ± 56 
Ischemic cardiomyopathy, no. (%) 51 (51)  
Non-ischemic cardiomyopathy, no. (%) 48 (49) 
NYHA functional class II, no. (%) 62 (63) 
NYHA functional class III, no. (%)  37 (37) 
NYHA functional class IV, no. (%)  0 (0) 
Medical Therapy 
Furosemide, no. (%) 88 (89) 
Furosemide dosage, mean ± SD 102 ± 105 
Antialdosterone, no. (%) 87 (88) 
ACE-inhibitors, no. (%) 62 (63) 
ARBs, no. (%) 25 (25) 
Beta-blockers, no. (%) 93 (94) 
Figure 1. Flow chart of the study design. ARNI: angiotensin receptor-neprilysin inhibitor; CPET:
cardiopulmonary exercise test; HFrEF: h art failure with reduc d ejection fraction.
Table 1. Patient characteristics at baseline (n = 99).
Demographics
Age, ean ± SD 58.7 ± 9.3
sex, no. (%) 14 (14)
SBP, , ean ± SD 117 ± 14
DBP, , ean ± SD 72 ± 10
Heart rate, be t min, mean ± SD 67 ± 11
Body mass index, kg m2, mean ± SD 28.1 ± 4.2
Medical History
Hypert n ion, no. (%) 51 (51)
Dia etes, no. (%) 34 (34)
Atrial fibrillation, no. (%) 17 (17)
COPD, no. (%) 10 (10)
eGFR, mL/min/1.73m2, mean ± SD 67.8 ± 23.7
Nt-pro-BNP, median (IQ range) 1200 (446–2120)
L EF (%), mean SD 27 ± 6
LVED , L, ean ± SD 218 ± 57
LVESV, mL, mean ± SD 153 ± 56
Ischemic cardiomyopathy, no. ( ) 51 (51)
Non-ischemic cardiomyopathy, no. (%) 48 (49)
NYHA functional class II, no. (%) 62 (63)
NYHA functional class III, no. (%) 37 (37)
NYHA functional class IV, no. (%) 0 (0)
Medical Therapy
Furosemide, no. ( ) 88 (89)
Furosemide dosage, mean ± SD 102 ± 105
Antialdosterone, no. (%) 87 (88)
ACE-inhibitors, no. (%) 62 (63)
ARBs, no. (%) 25 (25)
Beta-blockers, no. (%) 93 (94)
Ivabradine, no. (%) 20 (20)
Digoxin, no. (%) 7 (7)
Implantable cardioverter defibrillator, no. (%) 76 (77)
Cardiac resynchronization therapy, no. (%) 22 (22)
ACE: angiotensin-converting enzyme; ARB: angiotensin receptor inhibitor; COPD: chronic obstructive pulmonary
disease; DBP, diastolic blood pressure; eGFR: estimated glomerular filtration rate (as assessed by MDRD formula);
IQ: inter-quartile; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left
ventricular end-systolic volume; Nt-pro-BNP: N-terminal pro–B-type natriuretic peptide; NYHA: New York Heart
Association; SBP: systolic blood pressure; SD: standard deviation.
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At a median follow-up of 6.2 months (range 3–14.9 months), 28%, 38%, and 34% of the patients
were on 24/26 mg, 49/51 mg, and 97/103 mg of sacubitril/valsartan, respectively.
Patients characteristics in the sacubitril/valsartan low and high doses cohorts are reported
in Table 2.
Table 2. Patients characteristics in the sacubitril/valsartan low and high doses cohorts.
Sacubitril/Valsartan
24/26 mg
28 pts
Sacubitril/Valsartan
97/103 mg
34 pts
P value
Baseline Characteristics
Age, year, mean ± SD 57.8 ± 10.8 57.4 ± 8.6 0.87
Female sex, no. (%) 7 (25) 2 (6) 0.06
Ischemic cardiomyopathy, no. (%) 14 (50) 18 (53) 0.99
NYHA II, no. (%) 14 (50) 27 (79) 0.018
NYHA III, no. (%) 14 (50) 7 (21) 0.018
Diabetes, no. (%) 7 (25) 10 (29) 0.77
Atrial fibrillation, no. (%) 6 (21) 2 (6) 0.12
eGFR (MDRD), ml/min/1.73m2, mean ± SD 63.3 ± 21.6 72.6 ± 16.7 0.07
Furosemide dose, mean ± SD 108 ± 126 63 ± 95 0.03
Implantable cardioverter defibrillator, no. (%) 22 (78) 24 (70) 0.56
Cardiac resynchronization therapy, no. (%) 8 (28) 8 (23) 0.77
SBP, NT-pro-BNP, EDV, ESV, and LVEF (Baseline and Follow-up Data)
SBP, mmHg, mean ± SD (Baseline) 114.3 ± 12.1 120.5 ± 14.7 0.07
SBP, mmHg, mean ± SD (Follow-up) 96 ± 11 105 ± 12 0.004
Nt-pro-BNP, median (IQ range) (Baseline) 1623.5 (477–2947) 815 (358–1929) 0.013
Nt-pro-BNP, median (IQ range) (Follow-up) 1065 (376–1739) 394.5 (195–952) 0.01
LVEDV, ml, mean±SD (Baseline) 208 ± 54 222 ± 55 0.31
LVEDV, ml, mean±SD (Follow-up) 209 ± 56 209 ± 59 0.98
LVESV, ml, mean±SD (Baseline) 147 ± 57 161 ± 48 0.29
LVESV, ml, mean±SD (Follow-up) 146 ± 57 143 ± 50 0.89
LVEF (%), mean ± SD (Baseline) 28.1 ± 5.7 28.3 ± 5.1 0.88
LVEF (%), mean ± SD (Follow-up) 28.6 ± 6.3 32.3 ± 6.6 0.026
eGFR: estimated glomerular filtration rate (as assessed by MDRD formula); IQ: inter-quartile; LVEDV: left
ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left ventricular end-systolic
volume; Nt-pro-BNP: N-terminal pro–B-type natriuretic peptide; NYHA: New York Heart Association; SBP: systolic
blood pressure; SD: standard deviation.
3.2. CPET, NT-ProBNP, and Left Ventricular Function
Baseline and follow-up CPET results are shown in Table 3. At baseline, most patients were
classified as Weber Class C and Ventilatory Class II [14]; at follow-up, we observed a 17% increase in
peak VO2 (∆= +2.6 mL/kg/min, p < 0.0001), a 10.9% increase in percent predicted VO2 (p < 0.0001),
and a 16% increase in O2 pulse (∆= +1.9 mL/beat; p < 0.001), and an improvement in ventilatory
response with a 7% reduction in VE/VCO2 slope (∆= −2.4; p = 0.006). AT-VO2 increased from
11.3 ± 2.6 to 12.6 ± 3.5 mL/kg/min (p = 0.007); moreover, a 9% increase in ∆VO2/∆Work slope
(∆= +0.9 mL/beat; p = 0.0002) and a 25% increase in exercise tolerance (∆= +18 watt; p < 0.0001)
were obtained. At follow-up, systolic blood pressure significantly decreased from 117 ± 14 to
101 ± 12 mmHg (p < 0.0001) and 51 patients had a flat systolic blood pressure response during exercise
(51% at follow-up versus 34% at baseline, p = 0.021). Of note, this did not lead to sacubitril/valsartan
discontinuation in any patient.
At nominal logistic regression, increase in exercise tolerance (namely, 1-watt increase) was found
to be an independent predictor of 6% improvement of VO2 (OR = 1.06; 95% CI: 1.03–1.10; p < 0.0001) at
follow-up; a trend towards statistical significance was found with regard to VE/VCO2 slope decrease
(OR = 1.02; 95% CI: 0.99–1.04; p = 0.057).
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At follow-up, median NT-ProBNP levels decreased from 1344 (IQ range: 439–2191) to 631 pg/mL
(298–1554) (p = 0.002).
At follow-up, mean LVEF increased from 27 ± 6 to 29.7 ± 7% (p < 0.0001) and left ventricular
end-systolic volume decreased from 153 ± 56 to 145 ± 52 mL (p = 0.030).
Table 3. Cardiopulmonary exercise test parameters (n = 99).
Baseline Follow-up p value
Peak VO2, mL/kg/min, mean ± SD 14.6 ± 3.3 17.2 ± 4.7 <0.0001
Predicted peak VO2, %, mean ± SD 53.8 ± 14.1 64.7 ± 17.8 <0.0001
VE/VCO2 slope, mean ± SD 34.1 ± 6.3 31.7 ± 6.1 0.006
VE/VCO2 slope≥ 34, no. (%) 46 (46) 33 (33) 0.08
Peak RER, mean ± SD 1.12 ± 0.09 1.13 ± 0.09 0.45
Watt (Peak), mean ± SD 70 ± 22 88 ± 29 <0.0001
AT VO2, mL/kg/min, mean ± SD 11.3 ± 2.6 12.6 ± 3.5 0.007
Predicted AT VO2, %, mean ± SD 42.3 ± 11.5 47.2 ± 12.5 0.009
AT undetectable, no. (%), mean ± SD 16 (16) 9 (9) 0.19
O2pulse (ml/beat) 11.5 ± 3.0 13.4 ± 4.3 0.0007
∆VO2/∆work, mL/min/watt, mean ± SD 9.2 ± 1.5 10.1 ± 1.8 0.0002
Peak ventilation, L/min, mean ± SD 48.7 ± 12.7 59.3 ± 18.9 <0.0001
Peak tidal volume, L, mean ± SD 1.57 ± 0.43 1.75 ± 0.53 0.009
Peak Respiratory rate, b/m, mean ± SD 30.5 ± 6.7 33.3 ± 7.2 0.006
Ventilatory Oscillation, no. (%) 31 (31) 19 (19) 0.07
AT: anaerobic threshold; RER: respiratory exchange ratio; SD: standard deviation; VE/VCO2: minute
ventilation/carbon dioxide production ratio; VO2: oxygen consumption.
3.3. CPET Results Stratified by Sacubitril/Valsartan Dosages
Peak VO2 variation (baseline vs follow-up) was highest in patients taking 97/103 mg of
sacubitril/valsartan (∆= +3.4, p = 0.0009), as compared to patients taking low doses (24/26 mg) (∆= +2.0,
p = 0.09) and medium doses (49/51 mg) (∆= +2.1, p = 0.018) (full data reported in Table 4). A statistically
significant reduction in terms of VE/VCO2 slope was observed at follow-up in the subgroup of patients
on the highest dose of sacubitril/valsartan (p = 0.01; Table 4, Figure 2A). Of note, no statistically
significant differences were observed among these subgroups in terms of mean follow-up duration
and baseline Peak VO2 (Figure 2B).
Table 4. Cardiopulmonary exercise test parameters stratified by sacubitril/valsartan dosages.
Baseline Follow-up p value
Peak VO2, mL/kg/min, mean ± SD
24/26 mg dose (28 pts) 14.5 ± 3.9 16.5 ± 4.6 0.09
49/51 mg dose (37 pts) 14.2 ± 2.7 16.3 ± 4.5 0.018
97/103 mg dose (34 pts) 15 ± 3.2 18.4 ± 4.7 0.0009
Predicted peak VO2, %, mean ± SD
24/26 mg dose (28 pts) 54 ± 12.9 62.1 ± 14.1 0.029
49/51 mg dose (37 pts) 53.8 ± 13.9 61.9 ± 16.6 0.02
97/103 mg dose (34 pts) 53.6 ± 15.6 68.6 ± 20.6 0.001
VE/VCO2 slope, mean ± SD
24/26 mg dose (28 pts) 35.3 ± 6.8 32 ± 6.1 0.06
49/51 mg dose (37 pts) 34.8 ± 6.9 33.4 ± 6.9 0.4
97/103 mg dose (34 pts) 32.5 ± 4.9 29.5 ± 4.5 0.01
O2 pulse, ml/beat, mean ± SD
24/26 mg dose (28 pts) 11.4 ± 3.1 12.8 ± 4.3 0.016
49/51 mg dose (37 pts) 11 ± 3.1 12.3 ± 3.9 0.12
97/103 mg dose (34 pts) 12.2 ± 2.8 14.9 ± 4.4 0.003
∆VO2/∆work, mL/min/watt, mean ± SD
24/26 mg dose (28 pts) 9.1 ± 1.3 9.7 ± 2.2 0.24
49/51 mg dose (37 pts) 9 ± 1.6 9.9 ± 1.8 0.028
97/103 mg dose (34 pts) 9.3 ± 1.5 10.5 ± 1.4 0.001
SD: standard deviation; VE/VCO2: minute ventilation/carbon dioxide production ratio; VO2: oxygen consumption.
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Table 5. Cardiopulmonary exercise test parameters in patients stratified by follow-up duration. 
 Baseline Follow-up p value 
Peak VO2, mL/kg/min, mean ± SD 
     3 months (24 pts) 
     6 months (40 pts) 
    12 months (35 pts) 
 
15.3 ± 3 
14.8 ± 3.6 
13.8 ± 3 
 
16.9 ± 4.1 
17.1 ± 5 
17.3 ± 4.6 
 
.12 
.02 
.0006 
Predicted peak VO2, %, mean ± SD 
     3 months (24 pts) 
     6 months (40 pts) 
    12 months (35 pts) 
 
54.9 ± 9.5 
56.7 ± 14.5 
49.7 ± 15.6 
 
61.3 ± 13.1 
66.9 ± 17.2 
63.4 ± 20.4 
 
.06 
.0005 
.002 
VE/VCO2 slope, mean ± SD 
     3 months (24 pts) 
     6 months (40 pts) 
    12 months (35 pts) 
 
33.7 ± 6.2 
33.3 ± 6.6 
35.4 ± 6 
 
33.4 ± 7.8 
31.4 ± 6 
30.7 ± 4.8 
 
.90 
.19 
.0006 
O2 pulse, ml/beat, mean ± SD 
     3 months (24 pts) 
     6 months (40 pts) 
    12 months (35 pts) 
 
12.3 ± 3.3 
11.3 ± 3.2 
11.2 ± 2.5 
 
13.0 ± 4.2 
13.3 ± 4.3 
13.6 ± 4.5 
 
.52 
.023 
.007 
∆VO2/∆work, mL/min/watt, mean ± SD 
     3 months (24 pts) 
     6 months (40 pts) 
    12 months (35 pts) 
 
9.4 ± 1.4 
9.3 ± 1.2 
8.8 ± 1.7 
 
10.3 ± 1.7 
10.1 ± 2.1 
9.9 ± 1.7 
 
.09 
.042 
.007 
SD: standard deviation; VE/VCO2: minute ventilation/carbon dioxide production ratio; VO2: oxygen 
consumption  
4. Discussion 
CPET is a valuable tool to guide clinical decision-making and to derive prognostic information 
in HF patients [10,14–16]. 
In the PARADIGM-HF trial [1], sacubitril/valsartan reduced the risk of death and 
hospitalization for HF in patients with HFrEF, as compared to enalapril; however, little is known on 
how sacubitril/valsartan influences cardiopulmonary function.  
Figure 3. Panel A, VE/VCO2 slope variations at follow-up in patients stratified by baseline VE/VCO2
slope values. Panel B, Peak VO2 ri ti s t f ll -up in patients stratified by baseline VE/VCO2
slope values.
Patients who reached 12-month follow-up showed the greatest reduction in VE/VCO2 Slope
(∆= −4.7, p = 0.0006 for baseline versus follow-up), as compared to patients who only had 3- and
6-month follow-up (details of CPET parameters in patients stratified by follow-up duration shown
in Table 5).
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Table 5. Cardiopulmonary exercise test parameters in patients stratified by follow-up duration.
Baseline Follow-up p value
Peak VO2, mL/kg/min, mean ± SD
3 months (24 pts) 15.3 ± 3 16.9 ± 4.1 0.12
6 months (40 pts) 14.8 ± 3.6 17.1 ± 5 0.02
12 months (35 pts) 13.8 ± 3 17.3 ± 4.6 0.0006
Predicted peak VO2, %, mean ± SD
3 months (24 pts) 54.9 ± 9.5 61.3 ± 13.1 0.06
6 months (40 pts) 56.7 ± 14.5 66.9 ± 17.2 0.0005
12 months (35 pts) 49.7 ± 15.6 63.4 ± 20.4 0.002
VE/VCO2 slope, mean ± SD
3 months (24 pts) 33.7 ± 6.2 33.4 ± 7.8 0.9
6 months (40 pts) 33.3 ± 6.6 31.4 ± 6 0.19
12 months (35 pts) 35.4 ± 6 30.7 ± 4.8 0.0006
O2 pulse, ml/beat, mean ± SD
3 months (24 pts) 12.3 ± 3.3 13.0 ± 4.2 0.52
6 months (40 pts) 11.3 ± 3.2 13.3 ± 4.3 0.023
12 months (35 pts) 11.2 ± 2.5 13.6 ± 4.5 0.007
∆VO2/∆work, mL/min/watt, mean ± SD
3 months (24 pts) 9.4 ± 1.4 10.3 ± 1.7 0.09
6 months (40 pts) 9.3 ± 1.2 10.1 ± 2.1 0.042
12 months (35 pts) 8.8 ± 1.7 9.9 ± 1.7 0.007
SD: standard deviation; VE/VCO2: minute ventilation/carbon dioxide production ratio; VO2: oxygen consumption
4. Discussion
CPET is a valuable tool to guide clinical decision-making and to derive prognostic information in
HF patients [10,14–16].
In the PARADIGM-HF trial [1], sacubitril/valsartan reduced the risk of death and hospitalization
for HF in patients with HFrEF, as compared to enalapril; however, little is known on how
sacubitril/valsartan influences cardiopulmonary function.
To the best of our knowledge, this is the largest observational study prospectively assessing
the early effects of sacubitril/valsartan on cardiopulmonary parameters in patients with HFrEF.
After initiation of sacubitril/valsartan, we observed a significant improvement in the main
prognostically relevant CPET parameters. To date, only one study by Palau et al. [5] showed
an improvement in peak VO2 and VE/VCO2 slope in 33 HFrEF patients at 30 days follow-up after
sacubitril/valsartan initiation, mostly at low doses. In our study (entailing a larger population,
with a longer follow-up and including all available dosages of sacubitril/valsartan) we confirmed
the significant improvement in peak VO2 at follow-up (∆= +2.6 mL/kg/min; p < 0.0001); of note,
VE/VCO2 slope improvement started at 6 months from sacubitril/valsartan initiation and reached
a statistical significant difference only at 12 months (Table 5).
The observed improvement in peak VO2 (+17% versus baseline) and VE/VCO2 slope (−7%
versus baseline) at follow-up, might play a clinically and prognostically relevant role in this patient
population. Swank et al. [17] reported that for every 6% increase in peak VO2 there is an 8% reduction
in cardiovascular mortality or HF hospitalization (hazard ratio [HR] = 0.92; CI = 0.88–0.96; p < 0.001)
and a 7% reduction in all-cause mortality (HR = 0.93; CI = 0.90–0.97; p < 0.001). Arena et al. [18]
reported worse 1-year event-free survival from cardiac mortality (83.1% vs. 99.2%; p < 0.0001) and
worse 1-year event-free survival from cardiac hospitalization (50.6% vs. 84.6%; p < 0.0001) in patients
with VE/VCO2 slope ≥34 versus patients with VE/VCO2 slope <34. Furthermore, a large body of
evidence confirms the prognostic relevance of VE/VCO2 slope values [19–24].
Notably, at follow-up, sicker patients (i.e., patients with baseline VE/VCO2 ≥ 34) improved both
oxygen consumption and ventilatory efficiency while healthier patients (i.e., patients with baseline
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VE/VCO2 < 34) only improved oxygen consumption (Figure 3). Moreover, patients on the highest
doses of sacubitril/valsartan were found to be the ones with the best functional improvement (Figure 2).
These results are consistent with those reported in the PARADIGM-HF study [1].
A PARADIGM-HF post-hoc analysis by Vardeny et al. [25] demonstrates that lower doses of
sacubitril/valsartan confer a similar treatment benefit over enalapril; however, patients taking low
doses were associated with a higher risk of the primary events. In our study, patients taking low doses
had less improvement of peak VO2 as compared to patients taking the highest dose; this may reflect
patient frailty; indeed, patients taking low doses of sacubitril/valsartan showed lower systolic blood
pressure (both at baseline and at follow-up), higher levels of NT-proBNP, increased prevalence of
NYHA class III, higher furosemide dose use, lower estimated glomerular filtration rate, and a higher
VE/VCO2 slope at baseline (details provided in Tables 2 and 4).
Of note, exercise tolerance (namely, 1-watt increase) was found to be an independent predictor of
6% improvement of VO2 (OR = 1.06; 95% CI: 1.03–1.10; p < 0.0001) at follow-up, and a trend towards
statistical significance was found with regard to VE/VCO2 slope decrease (OR = 1.02; 95% CI: 0.99–1.04;
p = 0.057). It is likely that the weaker correlation with VE/VCO2 slope decrease might be due to the
small sample size of the study population.
Sacubitril/valsartan combines the effects of angiotensin receptor blocker with neprilysin inhibition
which amplify the system of natriuretic peptides and other vasoactive peptides [26,27]. However, little
is known about the overall effect of vasoactive peptides on heart and lung function. In our study
population, we observed an improvement of LVEF and a decrease of left ventricular end-systolic
volume at follow-up. We speculate that sacubitril/valsartan might have a synergistically favorable
effect on hemodynamics and muscle efficiency through reduced afterload and left ventricular filling
pressure. This might result in a net improvement of exercise tolerance and performance. Of note,
recent data (a longitudinal and a retrospective study) support an improvement in left ventricular
ejection fraction and in left ventricular reverse remodeling after sacubitril/valsartan initiation [28,29].
We also observed an increase in peak ventilatory responses which may be secondary to the
improvement of cardiac performance, allowing patients to increase ventilation without increasing the
VE/VCO2 slope, although, at the moment, this remains speculative.
5. Study Limitations
This study has a number of limitations. First, we had no control group. However, the patients
enrolled were hemodynamically stable and on optimized medical therapy; we may therefore
consider patients at first evaluation as their own controls (versus follow-up). Importantly, since
the PARADIGM-HF study has already demonstrated a relevant benefit of sacubitril/valsartan over
enalapril in this setting and it is now recommended by international guidelines [11,30], denying
sacubitril/valsartan to eligible patients in order to have a control group would have raised ethical
issues. Conversely, selecting patients not eligible for sacubitril/valsartan as the control group, might
have individuated frailer patients (i.e., with systolic arterial hypotension and more advanced chronic
renal failure). Secondly, an important limitation of this study is the small sample size; nonetheless, to
the best of our knowledge our work currently represents the largest series of HFrEF patients treated
with sacubitril/valsartan for whom follow-up CPET parameters have been tested. Unfortunately, no
data on diffusing capacity to carbon monoxide are available.
Further studies are necessary to confirm our preliminary results and to understand
sacubitril/valsartan influence on cardiopulmonary function. A clinical trial evaluating the effect
of sacubitril/valsartan on 6-month Exercise Tolerance in Patients with Heart Failure (NEPRIExTol) is
currently ongoing (NCT03190304).
6. Conclusions
In this prospective observational study, administration of sacubitril/valsartan was associated with
a significative improvement in exercise tolerance, peak oxygen consumption, and ventilatory efficiency
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at 6.2 months follow-up. Further studies are necessary to better clarify underlying mechanisms of this
functional improvement.
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